A Year 2, Long-Term, Open-Label, Safety Extension Study of the Combination of ABT-335 [ABT 335] and Statin Therapy [HMG-CoA reductase inhibitors] for Subjects With Mixed Dyslipidemia.

Trial Profile

A Year 2, Long-Term, Open-Label, Safety Extension Study of the Combination of ABT-335 [ABT 335] and Statin Therapy [HMG-CoA reductase inhibitors] for Subjects With Mixed Dyslipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2012

At a glance

  • Drugs Choline fenofibrate (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
  • Indications Dyslipidaemias
  • Focus Adverse reactions; Registrational
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Patient numbers amended from 300 to 310 as reported by ClinicalTrials.gov
    • 12 Jun 2008 The expected completion date for this trial is Nov 2008 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top